Nilotinib is a RTK inhibitor that targets Bcr-Abl, PDGFR, and c-Kit, and is also being used in a phase II clinical trial (NCT01201538) focusing on progressing vestibular schwannomas. The gene discussed is PDGFRB; the disease is Vestibular schwannoma.